


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims:

1. (Previously presented) A compound represented by the general formula I




Wherein

the dotted line ---- indicates a single bond or a double bond;

R^1, R^2, R^3, R^4, R^5 are independently selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yloxy, and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the

nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom; or

R^2 and R^3 together with the phenyl ring which they are attached form the structure represented by the formula



where R^1, R^4, R^5 are as defined above;

R^6 , R^7 , R^8 , R^9 are independently selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, hydroxy, hydroxy- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yloxy, and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom;


provided that at least one of R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , and R^9 is different from hydrogen:

or a pharmaceutically acceptable salt thereof.

2. (Previously presented) The compound of claim 1, wherein R¹ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, halo-C₁₋₆-alk(en/yn)yl, and NR^xR^y wherein R^x and R^y are

independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, and NR^zR^w-C₁₋₆-alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w-C₁₋₆-alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom.

3. (Previously presented) The compound of claim 1, wherein R² is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl.
4. (Previously presented) The compound of claim 1, wherein R³ is selected from the group consisting of hydrogen, halogen, cyano, C₁₋₆-alk(en/yn)yl, C₁₋₆-alk(en/yn)yloxy, C₁₋₆-alk(en/yn)ylsulfanyl, and halo-C₁₋₆-alk(en/yn)yl.
5. (Previously presented) The compound of claim 1, wherein R² and R³ together with the phenyl ring to which they are attached form the structure represented by the formula



6. (Previously presented) The compound of claim 1 wherein R^4 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, and halo- C_{1-6} -alk(en/yn)yl.
7. (Previously presented) The compound of claim 1 wherein R^5 is selected from the group consisting of hydrogen, halogen, cyano, C_{1-6} -alk(en/yn)yl, C_{1-6} -alk(en/yn)yloxy, C_{1-6} -alk(en/yn)ylsulfanyl, halo- C_{1-6} -alk(en/yn)yl, and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w - C_{1-6} -alk(en/yn)yl then the other is selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl; or R^x and R^y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom.
8. (Previously presented) The compound of claim 1 wherein R^6 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl.
9. (Previously presented) The compound of claim 1 wherein R^7 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, and halo- C_{1-6} -alk(en/yn)yl.
10. (Currently amended) The compound of claim 1 wherein R^8 is selected from the group consisting of hydrogen, halogen, C_{1-6} -alk(en/yn)yl, halo- C_{1-6} -alk(en/yn)yl, and NR^xR^y wherein R^x and R^y are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, cyano- C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, and NR^zR^w - C_{1-6} -alk(en/yn)yl, wherein R^z and R^w are independently selected from the group consisting of hydrogen, C_{1-6} -alk(en/yn)yl, C_{3-8} -cycloalk(en)yl, and C_{3-8} -cycloalk(en)yl- C_{1-6} -alk(en/yn)yl, provided that if one of R^x and R^y is NR^zR^w - C_{1-6} -alk(en/yn)yl then the other is selected from the group consisting of from

hydrogen, C₁₋₆-alk(en/yn)yl, cyano-C₁₋₆-alk(en/yn)yl, C₃₋₈-cycloalk(en)yl, and C₃₋₈-cycloalk(en)yl-C₁₋₆-alk(en/yn)yl; or R^X and R^Y together with the nitrogen to which they are attached form a 3-7-membered ring which optionally contains one further heteroatom.

11. (Previously presented) The compound of claim 1 wherein R⁹ is selected from the group consisting of hydrogen, halogen, C₁₋₆-alk(en/yn)yl, and halo-C₁₋₆-alk(en/yn)yl.

12. (Previously presented) The compound of claim 1 wherein the dotted line ---- indicates a single bond.

13. (Previously presented) The compound of claim 1 wherein the dotted line ---- indicates a double bond.

14. (Previously presented) The compound of claim 1 wherein the compound of formula I has 1-4 substituents in the phenyl ring(s), selected from any one of R¹-R⁹, which are different from hydrogen, and the remaining substituents are hydrogen.

15. (Previously presented) The compound of claim 1, said compound being selected from the group consisting of:

4-[2-(2,4-Dimethylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Chlorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluoro-2-methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Fluorophenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Methylphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(4-Methoxyphenoxy)phenyl]-1,2,3,6-tetrahydropyridine,
4-[2-(2,4-Dimethylphenoxy)phenyl]piperidine,
4-[2-(4-Chlorophenoxy)phenyl]piperidine,
4-[2-(4-Fluoro-2-methylphenoxy)phenyl]piperidine,
4-[2-(4-Fluorophenoxy)phenyl]piperidine,
4-[2-(4-Methylphenoxy)phenyl]piperidine,

4-[2-(4-Chloro-2- methyl-phenoxy)-phenyl]-piperidine
4-[2-(3-Chloro-2- methyl-phenoxy)-phenyl]-piperidine
4-[2-(2-Chloro-4-methyl-phenoxy)-phenyl]-piperidine
4-[2-(2,4-Dichloro-phenoxy)-phenyl]-piperidine
4-[2-(Benzo[1,3]dioxol-5-yloxy)-phenyl]-piperidine,
4-[2-(4-Methoxy-2-methyl-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dichloro-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dimethyl-phenoxy)-phenyl]-piperidine,
4-[2-(2,3,4,5-Tetramethyl-phenoxy)-phenyl]-piperidine,
4-[2-(4-Trifluoromethyl-phenoxy)-phenyl]-piperidine,
4-[2-(4-Methoxy-phenoxy)-phenyl]-piperidine,
4-[2-(2-Chloro-4-methoxy-phenoxy)-phenyl]-piperidine,
4-[2-(3,4-Dimethoxy-phenoxy)-phenyl]-piperidine, and
4-[2-(4-Chloro-3-trifluoromethyl-phenoxy)-phenyl]-piperidine;
or a pharmaceutically acceptable salt thereof.

16. (Previously presented) A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof and at least one pharmaceutically acceptable carrier or diluent.

17. (Cancelled)

18. (Previously presented) A method of treating a subject suffering from an affective disorder comprising administering to a subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof.

19. (Cancelled)

20. (Currently amended) The compound of claim 2 wherein R¹ is selected from the group consisting of hydrogen, C₁₋₆-alkyl, and halogen.

21. (Previously presented) The compound of claim 3 wherein R² is selected from the group consisting of hydrogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₁₋₆-alkyl, and halogen.
22. (Previously presented) The compound of claim 21 wherein R² is selected from the group consisting of hydrogen, and C₁₋₆-alkoxy.
23. (Previously presented) The compound of claim 4 wherein R³ is selected from the group consisting of hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, halogen, and halo-C₁₋₆-alkyl.
24. (Previously presented) The compound of claim 23 wherein R³ is selected from the group consisting of hydrogen, C₁₋₆-alkyl, C₁₋₆-alkoxy, and halogen.
25. (Previously presented) The compound of claim 6 wherein R⁴ is selected from the group consisting of hydrogen, C₁₋₆-alkoxy, halo-C₁₋₆-alkyl, C₁₋₆-alkyl, and halogen.
26. (Previously presented) The compound of claim 25 wherein R⁴ is selected from the group consisting of hydrogen, and C₁₋₆-alkoxy.
27. (Previously presented) The compound of claim 7 wherein R⁵ is selected from the group consisting of hydrogen, C₁₋₆-alkyl, and halogen.
28. (Previously presented) The compound of claim 8 wherein R⁶ is selected from the group consisting of hydrogen, and halogen.
29. (Previously presented) The compound of claim 9 wherein R⁷ is selected from the group consisting of hydrogen, and halogen.
30. (Previously presented) The compound of claim 10 wherein R⁸ is selected from the group consisting of hydrogen, halo-C₁₋₆-alkyl, C₁₋₆-alkyl, and halogen.
31. (Previously presented) The compound of claim 11 wherein R⁹ is hydrogen.

32. (Previously presented) The method of claim 18 wherein the affective disorder is depression.
33. (Previously presented) A method of treating a subject suffering from an anxiety disorder comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof.
34. (Previously presented) The method of claim 33 wherein the anxiety disorder is selected from the group consisting of general anxiety disorder, social anxiety disorder, post traumatic stress disorder, obsessive compulsive disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.